We are live on ! Find out more
KALV

KalVista Pharmaceuticals
KALV

Delisted

KALV was delisted on the 10th of June, 2026.

Back to rankings

91 hedge funds and large institutions have $234M invested in KalVista Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 27 increasing their positions, 29 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,124% more call options, than puts

Call options by funds: $1.1M | Put options by funds: $90K

7% less repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 29

8% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 24

2.76% less ownership

Funds ownership: 104.23% → 101.47% (-2.8%)

3% less funds holding

Funds holding: 94 → 91 (-3)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

34% less capital invested

Capital invested by funds: $357M → $234M (-$122M)

Holders
91
Holders Change
-3
Holders Change %
-3.19%
% of All Funds
1.46%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
22
Increased
27
Reduced
29
Closed
24
Calls
$1.1M
Puts
$90K
Net Calls
+$1.01M
Net Calls Change
-$8.87M

Top Buyers

Rank Fund Capital Flow
1
TCM
TCG Crossover Management
California
+$18.2M
2
VA
VR Adviser
New York
+$15.6M
3
FLSM
Frazier Life Sciences Management
California
+$8.93M
4
TCM
Tang Capital Management
California
+$7.48M
5
JFG
Jefferies Financial Group
New York
+$6.43M

Top Sellers

Rank Fund Capital Flow
1
DTC
Deep Track Capital
Connecticut
-$26.5M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$11.3M
3
IBT
International Biotechnology Trust
United Kingdom
-$4.59M
4
VC
Vivo Capital
California
-$3.63M
5
SCM
Suvretta Capital Management
New York
-$3.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$2.34M +$40.3K +7,525 +2%
JP Morgan Chase
27
JP Morgan Chase
New York
$2.21M +$1.02M +190,809 +140%
CC
28
Commodore Capital
New York
$2.11M – – –
Citigroup
29
Citigroup
New York
$1.87M +$1.48M +276,402 +41,316%
EAM
30
Eventide Asset Management
Massachusetts
$1.87M – – –
Northern Trust
31
Northern Trust
Illinois
$1.64M -$14.6K -2,733 -1%
Norges Bank
32
Norges Bank
Norway
$1.48M +$1.09M +204,000 +1,369%
AAA
33
Affinity Asset Advisors
New York
$1.27M +$493K +91,974 +95%
N
34
Nuveen
North Carolina
$982K -$58K -10,832 -14%
State of Wisconsin Investment Board
35
State of Wisconsin Investment Board
Wisconsin
$800K +$316K +59,071 +100%
Two Sigma Advisers
36
Two Sigma Advisers
New York
$758K -$13.4K -2,500 -2%
Susquehanna International Group
37
Susquehanna International Group
Pennsylvania
$725K +$574K +107,245 New
Citadel Advisors
38
Citadel Advisors
Florida
$686K -$204K -37,995 -27%
LCM
39
Laurion Capital Management
New York
$669K -$1.33M -248,110 -71%
AQR Capital Management
40
AQR Capital Management
Connecticut
$637K +$505K +94,284 New
Renaissance Technologies
41
Renaissance Technologies
New York
$637K -$160K -29,800 -24%
Connor, Clark & Lunn Investment Management (CC&L)
42
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$631K -$11.6K -2,173 -2%
Bank of New York Mellon
43
Bank of New York Mellon
New York
$561K +$1.53K +286 +0.3%
NFGH
44
Nan Fung Group Holdings
Hong Kong
$532K – – –
Charles Schwab
45
Charles Schwab
California
$427K – – –
CCMU
46
Cheyne Capital Management (UK)
United Kingdom
$357K +$283K +52,790 New
PP
47
PDT Partners
New York
$318K +$252K +47,044 New
D.E. Shaw & Co
48
D.E. Shaw & Co
New York
$296K -$2.44K -456 -1%
BC
49
Birchview Capital
Vermont
$270K – – –
RhumbLine Advisers
50
RhumbLine Advisers
Massachusetts
$254K +$386 +72 +0.2%
1
2
3 4 5

KALV Hedge Fund Activity: Q4 2022 in Review

91 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q4 2022, worth a combined $234M — down 34% from $357M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of KALV and 22 opened new positions — a net loss of 2 holders — while 29 trimmed existing stakes and 27 added.

The largest buyer was TCG Crossover Management, opening a new position worth an estimated $18.2M. The largest seller was Deep Track Capital, exiting entirely with an estimated $26.5M sold.

  • 91 institutional investors held KalVista Pharmaceuticals (KALV) as of Q4 2022, down from 94 in Q3 2022.
  • Funds reported $234M of KalVista Pharmaceuticals stock for Q4 2022, down 34% quarter-over-quarter.
  • 22 funds opened new KalVista Pharmaceuticals positions in Q4 2022 and 24 closed out, a net change of -2 holders.
  • The largest KalVista Pharmaceuticals buyer in Q4 2022 was TCG Crossover Management, an estimated $18.2M added.
  • The largest KalVista Pharmaceuticals seller in Q4 2022 was Deep Track Capital, an estimated $26.5M sold.

Based on aggregated 13F filings for Q4 2022.